These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 3083030)

  • 21. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil.
    Rieger A; Roisenberg I
    Thromb Haemost; 1999 Mar; 81(3):475-6. PubMed ID: 10102489
    [No Abstract]   [Full Text] [Related]  

  • 22. [Inhibitors against factor VIII in hemophilia. A review of treatment possibilities and personal results].
    Scheibel E; Feddersen C
    Ugeskr Laeger; 1985 Nov; 147(47):3803-7. PubMed ID: 3934824
    [No Abstract]   [Full Text] [Related]  

  • 23. [Hemophilia A with factor VIII inhibitor].
    Shima M
    Rinsho Ketsueki; 2003 Feb; 44(2):90-101. PubMed ID: 12692981
    [No Abstract]   [Full Text] [Related]  

  • 24. [Anti-factor VIII antibodies in children with hemophilia, and the management of hemorrhage].
    Klukowska A; Adamowicz-Salach A; Kamińska D; Zieleniewska B
    Pol Tyg Lek; 1987 Jul; 42(30):911-4. PubMed ID: 3118341
    [No Abstract]   [Full Text] [Related]  

  • 25. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A.
    Qian J; Borovok M; Bi L; Kazazian HH; Hoyer LW
    Thromb Haemost; 1999 Feb; 81(2):240-4. PubMed ID: 10063999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolerance to factor VIII inhibitors in hemophilia A patients: a French twist.
    Pascual V; Capra JD
    J Clin Invest; 1996 Mar; 97(6):1357-8. PubMed ID: 8617864
    [No Abstract]   [Full Text] [Related]  

  • 27. Factor VIII inhibitor with catalytic activity towards factor VIII.
    Lacroix-Desmazes S; Sooryanarayana ; Moreau A; Kazatchkine MD; Kaveri SV
    Haematologica; 2000 Oct; 85(10 Suppl):89-92. PubMed ID: 11187883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibodies to factor VIII in hemophilia A patients.
    Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
    Vox Sang; 2000; 78 Suppl 2():187-90. PubMed ID: 10938950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Acquired immunodeficiency in a patient with hemophilia].
    Alkan M; Kuperman O; Goldstein G; Berginer V
    Harefuah; 1986 Aug; 111(3-4):74-6. PubMed ID: 3098652
    [No Abstract]   [Full Text] [Related]  

  • 30. [Poly-electrolyte fractionated porcine factor VIII in the treatment of hemophilia A].
    Ferencz T; Skopál J; Csáki C; Laczkó M; Schuler D; Borsi J
    Orv Hetil; 1993 Dec; 134(52):2873-5. PubMed ID: 8272354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemophilia.
    Mariani G; Kroner BL; Brackmann HH
    N Engl J Med; 2001 Oct; 345(14):1066; author reply 1067. PubMed ID: 11586969
    [No Abstract]   [Full Text] [Related]  

  • 32. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
    Yee TT; Lee CA
    Thromb Haemost; 1999 May; 81(5):852. PubMed ID: 10365768
    [No Abstract]   [Full Text] [Related]  

  • 33. Burkitt-like lymphoma in a hemophilic boy with impaired cellular immunity.
    Aronis S; Tzortzatou F; Karaboulas K; Tsiftis G; Madalenakis K; Karpathios T
    Pediatrics; 1985 Aug; 76(2):289-91. PubMed ID: 3927255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Enzyme immunoassay of factor VIII-related antigen with observation in patients with von Willebrand's disease and hemophilia A (author's transl)].
    Okuda T; Masuyama H; Tanigawa T; Narihiro N; Fujimura Y; Takase T; Mikami S; Yoshioka A; Fukui H
    Rinsho Ketsueki; 1980 Jul; 21(7):946-52. PubMed ID: 6775115
    [No Abstract]   [Full Text] [Related]  

  • 35. Sequential clinical and immunologic abnormalities in hemophiliacs.
    Goldsmith JM; Kalish SB; Green D; Chmiel JS; Wallemark CB; Phair JP
    Arch Intern Med; 1985 Mar; 145(3):431-4. PubMed ID: 3919666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factor VIII inhibitors: a continuing problem.
    Hoyer LW
    J Lab Clin Med; 1993 Mar; 121(3):385-7. PubMed ID: 8445287
    [No Abstract]   [Full Text] [Related]  

  • 37. [Investigation and treatment of hemophilia A with inhibitor of factor VIII (author's transl)].
    Fukutake K; Fujimari M; Ukita M; Kitahara T
    Rinsho Ketsueki; 1973 Dec; 14(0):1393-99. PubMed ID: 4807613
    [No Abstract]   [Full Text] [Related]  

  • 38. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
    Baglin T; Beacham E
    Thromb Haemost; 1998 Dec; 80(6):1036-7. PubMed ID: 9869186
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical heterogeneity of acquired hemophilia A: a description of 4 cases.
    Franchini M; Girelli D; Olivieri O; Bozzini C; Guiotto M; Zardini G; Lippi G; Manzato F; Gandin G
    Haematologica; 2005 Mar; 90(3):ECR16. PubMed ID: 15753057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors.
    Orsini F; Rotschild C; Beurrier P; Faradji A; Goudemand J; Polack B
    Haematologica; 2005 Sep; 90(9):1288-90. PubMed ID: 16154861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.